Boai NKY Medical Holdings Ltd. (SHE:300109)

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007
Polyvinylpyrrolidone Series Other	673.07M
Polyvinylpyrrolidone Series Other Growth	11.77%
PolyvinylpyrrolidoneK30	492.15M
PolyvinylpyrrolidoneK30 Growth	-10.77%
Orici Series	182.93M
Orici Series Growth	16.67%
Polyvinylpyrrolidone-I	103.43M
Polyvinylpyrrolidone-I Growth	50.73%
Genetic Testing Technology Services	41.92M
Genetic Testing Technology Services Growth	-31.34%
Early Diagnosis of Tumors	41.11M
Early Diagnosis of Tumors Growth	-15.36%
Precision Medical Services	40.66M
Precision Medical Services Growth	-35.09%
Molecular Diagnostic Services	31.06M
Molecular Diagnostic Services Growth	-3.00%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007
China	1.32B
China Growth	45.32%
Overseas	852.15M
Overseas Growth	26.79%
Inter-segment Elimination	-570.09M